Key Takeaways Tempus AI integrates Median's FDA-cleared eyonis LCS into its Pixel imaging platform.TEM aims to enhance lung cancer detection, risk scoring and radiology workflow efficiency.Shares of TEM rose 2.3% post-announcement despite a 33.7% six-month decline.Tempus AI, Inc. (TEM) recently announced a collaboration with Median Technologies to integrate Median’s proprietary eyonis LCS solution into the Tempus Pixel platform. The integration is expected to expand Pixel’s AI capabilities in lung cancer sc ...

Key Takeaways HSIC is set to report Q4 2025 results on Feb. 24, with revenues projected to rise 4.5% year over year.Henry Schein's Global Specialty Products revenues are expected to grow 5.9% on implant strength.HSIC's Global Technology sales are projected to jump 9.7% on SaaS and cloud momentum.Henry Schein, Inc. (HSIC) is scheduled to release fourth-quarter 2025 results on Feb. 24, before the opening bell.In the last reported quarter, the company posted adjusted earnings per share (EPS) of $1.38, which su ...

Core Insights - The fourth quarter of 2025 saw a strong divergence in market performance, with AI beneficiaries and cyclical sectors leading, while quality growth strategies faced challenges [1] - The SGA Emerging Markets Growth Strategy portfolio returned 0.8% (Gross) and 0.6% (Net) in Q4 2025, underperforming against the MSCI EM Net TR Index return of 4.7% and the MSCI EM Growth Net TR Index return of 3.3% [1] - For the full year 2025, the portfolio achieved returns of 23.8% (Gross) and 22.8% (Net), lagging behind the indexes which returned 33.6% and 34.3% respectively [1] - The portfolio anticipates annual revenue growth of 13% and earnings growth of 16% over the next three years [1] Company Insights - Alcon Inc. (NYSE:ALC) is highlighted as a key stock in the SGA Emerging Markets Growth Strategy, focusing on eye care products [2] - Alcon Inc. experienced a one-month return of 0.25% and a 12.05% decline in share value over the past 52 weeks, with a closing stock price of $79.20 and a market capitalization of $39.052 billion as of February 13, 2026 [2] - The SGA Emerging Markets Growth Strategy engaged with Alcon's leadership team in December 2025 to discuss ESG matters, specifically compensation and sustainability [3]

Core Insights - Positron Corporation has announced the sale of four PET-CT 64-slice scanners to three nuclear cardiology practices, highlighting the growing adoption of its advanced imaging technology and services [1][2] Group 1: Company Developments - The new customer engagements reflect the increasing preference for Positron's next-generation PET-CT technology, which offers integrated clinical, technical, and training support [2] - Positron's PET-CT scanners are designed to optimize clinical outcomes and operational efficiency, featuring a 72cm wide-bore gantry for patient comfort and high-sensitivity detector technology to reduce radiation exposure [3][4] - The company has over three decades of experience in supporting clinical scans, positioning itself as a trusted partner for nuclear cardiology practices transitioning to PET-CT imaging [5] Group 2: Industry Context - The shift towards cardiac PET imaging is driven by the need for superior clinical performance and sustainable economics, as providers move away from legacy imaging modalities [3] - Positron's advanced data acquisition capabilities enhance diagnostic confidence and expand the range of studies that can be performed, including myocardial perfusion and tumor detection [4] - The company aims to expand the cardiac and oncology PET modality by delivering advanced technology and value to imaging specialists, supported by its partnership with Shenyang Intelligent Neuclear Technology Co. [9]

US equity futures woke up after President's Day and chose to resume their selloff (after a modest bounce on Monday's holiday failed to hold) dragged by Tech, as the risk-off moves on AI disruption fears continue. As of 8:15am ET, S&P 500 futures were down 0.5% with Nasdaq 100 contracts falling 1.0%. In premarket trading, all Mag 7 stocks are lower and Semis are being pressured with AVGO / NVDA lower by more than 1%. Pockets of outperformance (and higher absolute returns) can be found in Energy, Fins, Indu, ...

Executive team further strengthened with appointments of Teshtar Elavia to the newly created chief technology officer role, Michael Hutchinson as chief legal officer, and Kerri DiPietro as chief quality officer, representing decades of experience in the MedTech industry PRINCETON, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the appointment of Teshtar Elavia as corporate vice president and chief ...

Perimeter Announces Grant and Cancellation of Stock Options [Accessibility Statement] Skip NavigationTORONTO and DALLAS, Feb. 17, 2026 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announces its intention to enter into cancellation agreements with certain employees and consultants of the Company, pursuant to which it will cancel and grant stock options to such employees and consultants.The Company ...

Aetna joins Humana and United Healthcare in providing Medicare Advantage coverage for beneficiaries who meet medical necessity criteria for the ReWalk Personal Exoskeleton Together, these three national Medicare Advantage insurers represent approximately 16 million beneficiaries across the United States HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform ...

Core Insights - Sanara MedTech Inc. is participating in the TD Cowen 46th Annual Health Care Conference from March 2 – 4, 2026, with a presentation scheduled for March 3 at 9:10 a.m. Eastern Time [1] Company Overview - Sanara MedTech Inc. focuses on developing and commercializing transformative technologies aimed at improving clinical outcomes and reducing healthcare costs in the surgical market [3] - The company markets surgical products primarily in the North American surgical tissue repair market, including CellerateRX Surgical Activated Collagen Powder, BIASURGE Advanced Surgical Solution, and FORTIFY TRG Tissue Repair Graft [3] - Sanara aims to be an innovative provider of effective surgical solutions and is committed to expanding its product offerings for patients in the United States [3]

Change in ADS ratio aimed at simplifying comparisons to ordinary shares traded on the Tel Aviv Stock Exchange, while boosting liquidity and access for U.S. investorsBURLINGTON, Mass. and JERUSALEM, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that its Board of Directors approved a plan to change to the ratio of its American Depositary Shares (ADSs) listed on the N ...